source
- Rezera files for IPO to back NLRP3 work in peripheral artery diseaseRezera, the biotech that rebranded from NodThera earlier this year, has entered the queue for an initial public offering to bolster its decade-long NLRP3 efforts. The biotech submitted its pitch We…Endpoints · 18m ago↗ source
- China biotech RiboX reveals first data of circular RNA therapies in peopleBiotech investors and pharma companies have poured billions into three Boston-region startups competing to develop a next-generation version of mRNA technology that could make for more durable and…Endpoints · 45m ago↗ source
- Genmab faces steep revenue cliff as Darzalex patents expire, eyes pivotal Epkinly readoutGenmab relies heavily on Darzalex, a cancer drug co‑developed with Johnson & Johnson, which currently provides about 90% of the company’s sales. U.S. patents for Darzalex are set to expire in 2029,…